(Nano) systems with active targeting to sensitize colorectal cancer stem cells to anti-tumoral treatment

Acronym: Target4Cancer
Coordinator: Simo Schwartz Jr. CIBBIM-Nanomedicine; Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca, Barcelona, Spain; simo.schwartz@vhir.org
Partners: Stefania Scala, Mafalda Videira, Ling Peng, Ming Wei

Even though current treatments have improved the overall survival of patients with colon cancer, relapse and development of therapy-resistant metastases are still frequent. This project will develop Drug Delivery Systems targeting cancer stem cells to improve the therapeutic window of Doxorubicin and/or AKT2 siRNA against colorectal cancer. In vitro and in vivo preclinical validation will be performed to select the best performing nano-conjugate targeting for future scale-up and regulatory studies. The project is expected to produce clinical useful proof-of-concept results suitable for protection by patenting, as well as data of general scientific interest useful to the broad scientific community.

“Drug Delivery Systems targeting cancer stem cells to improve the therapeutic window”